New Omicron Boosters add Limited Protection Against COVID-19 illness, Experts say
(CTN News) – However, experts predict that the new omicron boosters will help keep the elderly and other vulnerable populations out of hospitals this winter, even if they are probably not particularly successful in preventing Covid infections and mild illnesses.
According to real-world research by the Centers for Disease Control and Prevention released this week, the omicron boosters are less than 50% effective against mild sickness across almost all adult age categories. This is when compared to unvaccinated persons.
When given as their fourth dose, the booster was 19% more efficient than the unvaccinated at avoiding mild sickness in seniors. On the fifth dosage, it had a 23% success rate against moderate sickness.
People who got the omicron boosters fared better than those who did not, despite the vaccine’s modest benefit against mild sickness.
Depending on the age and when the previous dosage was administered, the booster enhanced people’s protection against mild sickness by 28% to 56% compared to those who had just got the old injections.
To achieve the high levels of protection the vaccinations displayed in late 2020 and early 2021, the Food and Drug Administration approved the boosters in late August.
The vaccinations were then more than 90% efficient in preventing infection. However, the CDC’s first real-world data shows that the boosters aren’t living up to those lofty promises.
John Moore, a professor of microbiology and immunology at Weill Cornell Medical College, stated that while the omicron boosters provide some extra protection, they are ineffective against infection.
According to Moore, those more susceptible to Covid should obtain a booster since it only slightly improves protection.
But he said that while the boosters aren’t very successful in preventing infection, common sense precautions like masking and avoiding crowded places still serve as useful tools for susceptible populations.
When omicron BA.5 was predominant from September through November, the CDC investigation focused on more than 360,000 persons with healthy immune systems who tested positive for Covid at retail pharmacies.
The subjects either received the booster injection, two or more doses of the previous vaccinations, or they were not immunized. The individuals who tested positive for Covid were then contrasted with those who did not.
It is still unknown if the omicron boosters will provide greater protection against hospitalization than the conventional injections since the research did not assess how well the boosters functioned against serious illness.
In a statement, the CDC promised to provide information on more serious outcomes as soon as it is available.
In a period of highly immunological evasive omicron subvariants, Andrew Pekosz, a virologist at Johns Hopkins University, said that the fact that the injections provide some protection against infection is a solid indication that they will offer robust protection against hospitalization.
He says immunizations have always worked better against severe sickness than a mild illness. “It’s preferable to nothing. It doesn’t necessarily indicate that the level of protection against infection is really great, according to Pekosz.
Then, I would anticipate seeing substantially more protection against hospitalization or mortality.
Since the antibodies that block infection diminish over time, Dr. Paul Offit, a member of the FDA’s vaccine advisory council, said that aiming to prevent mild sickness is not a workable public health approach.
“In the omicron subvariant period, protection against mild illness isn’t that good. Offit, a specialist in infectious diseases at Children’s Hospital of Philadelphia who worked on the rotavirus vaccine, said the aim was to protect against serious illness.
According to Dr. Celine Gounder, a senior public health fellow at the Kaiser Family Foundation, the statistics are not alarming.
Even a small reduction in individual risk may substantially benefit population-level public health.
Given that the elderly account for 90% of COVID fatalities, Gounder said it would be substantial to cut risk among them by even 30% or 20%.
For me, the most important thing is if you can keep the 65-year-old out of the hospital.
The omicron boosters, also known as bivalent vaccinations, target the 2019 Covid strain that initially appeared in Wuhan, China and omicron BA.5.
The first doses, also known as monovalent vaccinations, only contain the first strain of Covid.
The effectiveness of the omicron boosters against more immune evasive omicron subvariants, including BQ.1 and BQ.1.1, which are now prevalent in the U.S., is yet unknown.
According to Pfizer and Moderna last week, early results from human trials reveal that the omicron boosters trigger an immune response against these subvariants.
According to CDC statistics, 35 million out of the 41 million persons eligible for the new booster have already gotten it. A little over 30% of seniors have had a shot.
Related CTN News:
U.K. Approves New Moderna Vaccine Targeting Omicron Variant